2.9565
price down icon4.63%   -0.1435
after-market アフターアワーズ: 3.00 0.0435 +1.47%
loading
前日終値:
$3.10
開ける:
$3.178
24時間の取引高:
1,629
Relative Volume:
0.20
時価総額:
$4.55M
収益:
$2.54M
当期純損益:
$-4.13M
株価収益率:
-1.0751
EPS:
-2.75
ネットキャッシュフロー:
$-4.11M
1週間 パフォーマンス:
-1.45%
1か月 パフォーマンス:
-4.63%
6か月 パフォーマンス:
-33.71%
1年 パフォーマンス:
-25.72%
1日の値動き範囲:
Value
$2.9075
$3.178
1週間の範囲:
Value
$2.9075
$3.2999
52週間の値動き範囲:
Value
$2.20
$5.20

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name
名前
Xenetic Biosciences Inc
Name
セクター
Healthcare (1171)
Name
電話
781-778-7720
Name
住所
945 CONCORD ST., FRAMINGHAM, MA
Name
職員
2
Name
Twitter
@XeneticBio
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
XBIO's Discussions on Twitter

XBIO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
XBIO
Xenetic Biosciences Inc
2.9565 4.60M 2.54M -4.13M -4.11M -2.75
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.232 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.34 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 65.36B 14.09B 4.50B 2.96B 39.28

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-01-08 開始されました Maxim Group Buy

Xenetic Biosciences Inc (XBIO) 最新ニュース

pulisher
May 31, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World

May 31, 2025
pulisher
May 17, 2025

Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

May 17, 2025
pulisher
May 17, 2025

Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World

May 17, 2025
pulisher
May 14, 2025

Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire

May 14, 2025
pulisher
May 14, 2025

Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post

May 14, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World

May 08, 2025
pulisher
May 06, 2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com

May 06, 2025
pulisher
May 05, 2025

Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 04, 2025

Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire

May 04, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 01, 2025

Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World

May 01, 2025
pulisher
Apr 28, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 27, 2025

Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 26, 2025

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 25, 2025

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

Xenetic Biosciences, Inc. to Present at BIO Investor Forum - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM) - ACCESS Newswire

Apr 25, 2025

Xenetic Biosciences Inc (XBIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.29%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
大文字化:     |  ボリューム (24 時間):